Sandoz's Rebecca Guntern: Bio100 ambition rests on "selecting the right assets" and end-to-end control
Swiss generics and biosimilars major's chief commercial officer tells The Pharma Letter that disciplined pipeline selection, in-house manufacturing and 20 years of launch experience are what separate Sandoz from a crowded field of biosimilar challengers.
Sandoz (SIX: SDZ) used its Capital Markets Day on Tuesday to set out Bio100, an ambition to grow its biosimilar portfolio from 13 marketed products today to more than 100 by 2040, while expanding the share of biosimilar-addressable loss-of-exclusivity value it covers from around 50% currently to roughly 80% from 2035.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze